Medicare covers certain GLP-1 medications in 2027, but your coverage depends on your diagnosed health conditions and chosen program pathway. Obtaining these treatments requires navigating specific rules.
A federal statute still prohibits standard Medicare Part D plans from paying for medications prescribed solely for weight loss. Because of this restriction, you cannot simply obtain coverage for weight management under standard Part D benefits.
Fortunately, Medicare offers coverage pathways through secondary health conditions and a temporary federal demonstration project. Understanding these options helps you avoid paying thousands of dollars out of pocket.
Standard Medicare Part D Rules for Ozempic and Wegovy
When you review your Medicare prescription drug coverage, you must understand the legal boundary separating weight loss from chronic disease treatment.
The law governing Medicare Part D explicitly bans coverage for drugs used solely for weight loss or weight gain, an exclusion Congress wrote into the Medicare modernizing legislation in 2003.
Because of this rule, private Part D plans cannot add medications to their formularies solely to help enrollees lose weight.
However, the restriction applies strictly to the diagnosis rather than the medication itself. Many popular weight-management medications treat other serious, life-threatening medical conditions.
Covered Indications for Ozempic
Ozempic contains the active ingredient semaglutide, which functions as a glucagon-like peptide-1 (GLP-1) receptor agonist. The Food and Drug Administration (FDA) approved Ozempic specifically to lower blood sugar in adults with type 2 diabetes.
If your doctor diagnoses you with type 2 diabetes, your standard Medicare Part D plan covers Ozempic to improve glycemic control and reduce cardiovascular risks associated with diabetes.
Conversely, if your physician prescribes Ozempic strictly for weight reduction without a diabetes diagnosis, your Part D plan will automatically deny the claim.
Covered Indications for Wegovy
Wegovy also contains semaglutide, but manufacturers package it at higher maintenance doses specifically designed for weight management. For years, Medicare plans could not cover Wegovy under any circumstances.
A major policy shift occurred when the FDA approved Wegovy to reduce major cardiovascular risks. According to a KFF analysis of Medicare Part D rules, this decision created a legal pathway for standard coverage.
Standard Part D plans must cover Wegovy when you have established cardiovascular disease alongside obesity or overweight to prevent future heart attacks and strokes.
Other GLP-1 Coverage Under Part D
Medicare applies this diagnostic standard to other metabolic drugs. For example, standard Part D plans cover Zepbound (tirzepatide) for specific medical conditions beyond weight loss.
You can receive Part D coverage for Zepbound if diagnosed with moderate-to-severe obstructive sleep apnea or metabolic dysfunction-associated steatohepatitis (fatty liver disease).
Without one of these approved diagnoses, your Part D plan cannot pay for the medication under standard rules.
